We are live on ! Find out more
SPRY icon

ARS Pharmaceuticals
SPRY

76 hedge funds and large institutions have $864M invested in ARS Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 25 increasing their positions, 19 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 10

32% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 19

12% more funds holding

Funds holding: 68 → 76 (+8)

0.58% more ownership

Funds ownership: 79.6% → 80.18% (+0.58%)

28% less capital invested

Capital invested by funds: $1.21B → $864M (-$341M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
76
Holders Change
+8
Holders Change %
+11.76%
% of All Funds
1.32%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
18
Increased
25
Reduced
19
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WA
Wasatch Advisors
Utah
+$12.2M
2
NCM
Nantahala Capital Management
Connecticut
+$8.79M
3
CS
Candriam SCA
Luxembourg
+$6.3M
4
WP
Woodline Partners
California
+$5.48M
5
ECM
Endurant Capital Management
California
+$4.46M

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$10.9M
2
CAM
Cormorant Asset Management
Massachusetts
-$8.37M
3
LGM
Logos Global Management
California
-$5.45M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.41M
5
VA
VR Adviser
New York
-$3.71M
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$3.89M -$278K -8,686 -6%
RPAM
27
Rhenman & Partners Asset Management
Sweden
$3.09M +$3.21M +100,000 New
CC
28
Commodore Capital
New York
$3M – – –
Charles Schwab
29
Charles Schwab
California
$2.65M +$44.6K +1,391 +2%
PAMU
30
Pictet Asset Management (UK)
United Kingdom
$2.32M -$101K -3,147 -4%
N
31
Nuveen
North Carolina
$1.73M +$184K +5,741 +11%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$1.22M +$152K +4,732 +14%
Citadel Advisors
33
Citadel Advisors
Florida
$1.07M +$1.11M +34,648 New
Bank of America
34
Bank of America
North Carolina
$1.03M +$207K +6,459 +24%
SCM
35
Soleus Capital Management
Connecticut
$967K -$2.11M -65,950 -68%
Victory Capital Management
36
Victory Capital Management
Texas
$895K -$60.9K -1,900 -6%
HS
37
HighVista Strategies
Massachusetts
$800K +$380K +11,839 +84%
Swiss National Bank
38
Swiss National Bank
Switzerland
$714K +$741K +23,100 New
BOTOTLSJU
39
Board of Trustees of The Leland Stanford Junior University
California
$672K – – –
California State Teachers Retirement System (CalSTRS)
40
California State Teachers Retirement System (CalSTRS)
California
$542K -$50.7K -1,582 -8%
RhumbLine Advisers
41
RhumbLine Advisers
Massachusetts
$515K +$112K +3,491 +26%
Janney Montgomery Scott
42
Janney Montgomery Scott
Pennsylvania
$498K +$7.95K +248 +2%
Man Group
43
Man Group
United Kingdom
$415K +$431K +13,443 New
Morgan Stanley
44
Morgan Stanley
New York
$408K +$424K +13,224 New
Ohio Public Employees Retirement System (OPERS)
45
Ohio Public Employees Retirement System (OPERS)
Ohio
$386K – – –
New York State Common Retirement Fund
46
New York State Common Retirement Fund
New York
$352K +$119K +3,709 +48%
EMG
47
ETF Managers Group
New Jersey
$325K -$13.8K -431 -4%
JP Morgan Chase
48
JP Morgan Chase
New York
$281K -$617K -19,255 -68%
Squarepoint
49
Squarepoint
New York
$281K +$292K +9,101 New
Jane Street
50
Jane Street
New York
$281K +$292K +9,111 New
1
2
3 4

SPRY Hedge Fund Activity: Q2 2021 in Review

76 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q2 2021, worth a combined $864M — down 28% from $1.21B a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new SPRY positions and 10 closed out — a net gain of 8 holders — while 25 added to existing stakes and 19 trimmed.

The largest buyer was Wasatch Advisors, adding an estimated $12.2M. The largest seller was BlackRock, cutting an estimated $10.9M.

  • 76 institutional investors held ARS Pharmaceuticals (SPRY) as of Q2 2021, up from 68 in Q1 2021.
  • Funds reported $864M of ARS Pharmaceuticals stock for Q2 2021, down 28% quarter-over-quarter.
  • 18 funds opened new ARS Pharmaceuticals positions in Q2 2021 and 10 closed out, a net change of +8 holders.
  • The largest ARS Pharmaceuticals buyer in Q2 2021 was Wasatch Advisors, an estimated $12.2M added.
  • The largest ARS Pharmaceuticals seller in Q2 2021 was BlackRock, an estimated $10.9M sold.

Based on aggregated 13F filings for Q2 2021.